PDF(992 KB)
Efficacy and safety of adjunctive levetiracetam in children younger than 4 years with refractory epilepsy
HU Yan, LIAO Jian-Xiang, CHEN Li, HUANG Tie-Shuan, LI Bing
Chinese Journal of Contemporary Pediatrics ›› 2010, Vol. 12 ›› Issue (04) : 256-258.
PDF(992 KB)
PDF(992 KB)
Efficacy and safety of adjunctive levetiracetam in children younger than 4 years with refractory epilepsy
OBJECTIVE: To evaluate of the efficacy and safety of adjunctive levetiracetam (LEV) in children younger than 4 years with refractory epilepsy. METHODS: One hundred and twelve children at age of 4 months to 4 years with refractory epilepsy received LEV as adjunctive therapy. LEV was administered in two equal daily doses of 10 mg/kg. The dose was increased by 10 mg/kg every week up to the target dose (20-40 mg/kg). The efficacy and tolerability were evaluated. RESULTS: At an average follow-up period of 13 months (6-22 months), LEV administration was found to be effective in 43 children (38.4%) (responders showing more than a 50% decrease in seizure frequency) and 14 children (12.5%) became seizure-free. Fifty-three children (47.3%) did not respond to the treatment and 2 children (1.8%) worsened. The therapy-related adverse events were mild, including restlessness,. reduction in sleep time, night terrors, debility, somnolence, nausea and vomiting. The adverse events were either tolerable or resolved in time with dosage reduction in most of children, and only 3 cases required discontinuation. CONCLUSIONS: LEV as adjunctive therapy is effective and well-tolerated in children younger than 4 years with refractory epilepsy, suggesting that it represents a valid option for the treatment of refractory epilepsy in this age group.［Chin J Contemp Pediatr, 2010, 12 (4):256-258］
［1］Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3 000 mg/d in patients with refractory partial seizures:a multicenter, double-blind, responder-selected study evaluating monotherapy.European Levetiracetam Tolerability Study Group［J］. Epilepsia, 2000, 41(10):1276-1283.
［2］Leppik IE, Biton V, Sander JW, Wieser HG. Levetiracetam and partial seizure subtypes: pooled data from three randomized,placebo-controlled trials［J］.Epilepsia, 2003, 44(12):1585-1587.
［3］吴洵，洪震，吴逊，吴立文，赵忠新，王学峰，等. 多中心、双盲、随机、安慰剂对照评价左乙拉西坦添加治疗难治性部分性癫癎发作的疗效及安全性［J］.中华神经科杂志, 2007, 40(3):149-153.
［4］Shoemaker MT, Rotenberg JS. Levetiracetam for the treatment of neonatal seizures［J］. J Child Neurol, 2007, 22(1):95-98.
［5］Perry MS, Benatar M.Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review［J］. Epilepsia, 2007, 48(6):1123-1127.
［6］Grosso S, Cordelli D, Franzoni E, Coppola G, Capovilla G, Zamponie N, et al.Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy［J］.Seizure, 2007, 16(4):345-350.
［7］Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic veskle protein SV2A is the binding site for the antiepileptic drug levetiracetam［J］. Proc Natl Acad Sci USA, 2004, 101(26):9861-9866.
［8］Korea Topiramate Study Group.Topiramate in medically intractable partial epilepsisies:double-blind placebo-controlled randomized parallel group trial［J］.Epilepsia, 1999, 40(12):17671774.
［9］李世绰, 吴立文.临床诊疗指南·癫癎病分册［M］.北京:人民卫生出版社，2007：41-43.
